SERTAD1 and plasma cell myeloma: As shown in Figure 2, SERTAD1 acts as a potential carcinogenic driver in most of the cancers such as invasive breast cancer, glioblastoma, teratoma, myeloma and pancreatic ductal carcinoma (Table 1).